In this exploratory analysis of the overall trial population, adjuvant TAGRISSO reduced the risk of disease recurrence or death by 84% in patients who had been treated with prior adjuvant chemotherapy ...
Results underscore TAGRISSO as 1st-line standard of care and backbone therapy in EGFRm lung cancer across stages WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the final overall survival ...
SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to TAGRISSO upon disease progression demonstrates strong clinical activity Susan Galbraith, ...
Longer-term follow up in the FLAURA2 Phase III trial confirms the favorable benefit-risk profile of this combination Overall survival results reinforce TAGRISSO as the backbone therapy in EGFRm lung ...
Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in EGFR-mutated non-small cell lung cancer, both as monotherapy and in combination therapies. These results, ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been granted Breakthrough Therapy Designation (BTD) in the US for the adjuvant treatment of patients with early-stage (IB, ...
The three-drug combination of Tagrisso plus platinum-based chemotherapy and pemetrexed boosted outcomes for patients with EGFR-mutant advanced non-small cell lung cancer. Tagrisso(osimertinib) ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of ...
In LAURA Phase III trial, Tagrisso continues to demonstrate improved overall survival trend in unresectable, Stage III setting SAVANNAH and ORCHARD Phase II trials show the addition of Orpathys or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results